{"id":"NCT04497987","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-02","primaryCompletion":"2021-01-16","completion":"2021-05-20","firstPosted":"2020-08-04","resultsPosted":"2022-02-04","lastUpdate":"2022-02-04"},"enrollment":1180,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19","SARS-CoV2"],"interventions":[{"type":"DRUG","name":"Bamlanivimab","otherNames":["LY-CoV555","LY3819253"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Etesevimab","otherNames":["LY-CoV016","LY3832479"]}],"arms":[{"label":"Bamlanivimab (Part 1)","type":"EXPERIMENTAL"},{"label":"Placebo (Part 1)","type":"PLACEBO_COMPARATOR"},{"label":"Bamlanivimab (Part 2-Prevention)","type":"EXPERIMENTAL"},{"label":"Bamlanivimab + Etesevimab (Part 2-Prevention)","type":"EXPERIMENTAL"},{"label":"Placebo Comparator: Placebo (Part 2-Prevention)","type":"PLACEBO_COMPARATOR"},{"label":"Bamlanivimab (Part 2 - Treatment)","type":"EXPERIMENTAL"},{"label":"Bamlanivimab + Etesevimab (Part 2- Treatment)","type":"EXPERIMENTAL"},{"label":"Bamlanivimab (Part 3)","type":"EXPERIMENTAL"},{"label":"Bamlanivimab + Etesevimab (Part 3)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.","primaryOutcome":{"measure":"Percentage of Participants With COVID-19","timeFrame":"Week 8 after randomization","effectByArm":[{"arm":"Placebo","deltaMin":15.7,"sd":null},{"arm":"4200mg Bamlanivimab","deltaMin":8.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["35713300","34473343","34374951","34081073"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6hAC2UjP12uxz1fFWVGSKC"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":587},"commonTop":["Urinary tract infection","Hypertension","Fall","Arthralgia","Back pain"]}}